Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts.
Michael T. Lotze
No relevant relationships to disclose
Leonard Joseph Appleman
Research Funding - Bayer
Ramesh K. Ramanathan
Research Funding - Bayer
Anthony W. Tolcher
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Muralidhar Beeram
No relevant relationships to disclose
Kyriakos P. Papadopoulos
Research Funding - Bayer
Drew Warren Rasco
Research Funding - Bayer
Glen J. Weiss
Consultant or Advisory Role - Bayer
Research Funding - Bayer
James M Mountz
No relevant relationships to disclose
Frederico G.S. Toledo
No relevant relationships to disclose
Rene J Alvarez
No relevant relationships to disclose
Matthew J Oborski
No relevant relationships to disclose
Prabhu Rajagopalan
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Michael Jeffers
Employment or Leadership Position - Bayer
Diane Roth
Employment or Leadership Position - Bayer (I)
Ronald L. Dubowy
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Amita Patnaik
Research Funding - Bayer